Vera Therapeutics (VERA) Research & Development (2020 - 2026)

Vera Therapeutics has reported Research & Development for 7 years, with the latest figure at $86.0 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 108.37% year-over-year to $86.0 million; the trailing twelve-month figure through Mar 2026 stood at $260.0 million (up 80.24% YoY), and the FY2025 full-year result was $215.3 million, up 70.61% from the prior year.
• Research & Development for Q1 2026 stood at $86.0 million, up from $59.3 million in the prior quarter.
• The five-year high for Research & Development was $86.0 million in Q1 2026, with the low at $3.7 million in Q3 2022.
• Historically, Research & Development has averaged $35.1 million across 5 years, with a median of $29.3 million in 2024.
• Annual changes were most pronounced in 2022 — Research & Development jumped 2490.81% — and 2023, when it slumped 68.17%.
• Vera Therapeutics' Research & Development stood at $65.3 million in 2022, then tumbled by 68.17% to $20.8 million in 2023, then soared by 60.44% to $33.3 million in 2024, then jumped by 77.86% to $59.3 million in 2025, then soared by 45.02% to $86.0 million in 2026.
• The last three Research & Development figures came in at $86.0 million (Q1 2026), $59.3 million (Q4 2025), and $56.5 million (Q3 2025), per Business Quant data.